ClinicalTrials.gg
CompletedNCT00522379Updated Oct 27, 2014Results posted

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

A Phase 3 interventional study of Rotigotine and Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Completed at 77 sites in 5 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-10-27.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
Largest of 42
514 · median 123
Started
2007
with 5 others
Phase 3
20 of 44
none open now
Registered
12th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one has the largest enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 12th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.

Read the detailed description

To maintain treatment blind, two different active patch sizes were used (10 cm\^2 \& 20 cm\^2). Placebo patches matched according to size and appearance. During the trial subjects applied up to three patches, active and placebo, to achieve their assigned daily dose.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's disease
  • rotigotine
  • patch
  • transdermal
  • dopamine agonist
  • off time
  • Neupro
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PD greater than 3 years
  • Stable dose L-dopa but symptoms not adequately controlled and have "off" time
  • Able and willing to complete diary on specific days

Exclusion criteria

Exclusion Criteria:

  • Previous use of rotigotine or Neupro
  • Atypical Parkinson's syndrome
  • Pallidotomy
  • Thalamotomy
  • Deep brain stimulation
  • Fetal tissue transplant
  • Dementia
  • Psychosis
  • Hallucinations
  • Epilepsy
  • Renal or hepatic dysfunction
  • cardiac dysfunction
  • Symptomatic orthostatic hypotension
  • Skin sensitivity to adhesives or unresolved contact dermatitis
  • History of chronic alcohol or drug abuse
  • Pregnant or of
  • Impulse control disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    Rotigotine 2 mg/24 hr

    Drug: Rotigotine

  • Experimental
    Rotigotine 4 mg/24 hr

    Drug: Rotigotine

  • Experimental
    Rotigotine 6 mg/24 hr

    Drug: Rotigotine

  • Experimental
    Rotigotine 8 mg/24 hr

    Drug: Rotigotine

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • 2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

    Also known as: Neupro

  • 4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks

    Also known as: Neupro

  • OtherPlacebo

    Placebo transdermal patch applied daily

  • 6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks

    Also known as: Neupro

  • 8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

    Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

Secondary outcomes

  1. The Change in Relative Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

    Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  2. The Change in the Absolute Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

    Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  3. The Change in the Relative Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

    Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  4. The Change in the Status of the Subject After Wake-Up From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  5. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II From Baseline to the End of the Maintenance Period

    The Unified Parkinson's Disease Rating Scale (UPDRS) Part II is a scale for the assessment of function in Parkinson's disease. UPDRS Part II measures Activities of Daily Living. It consists of 13 questions, each ranging from 0 to 4. The sum score of the UPDRS Part II ranges from 0 to 52. A higher score indicates greater disability. A negative change score indicates improvement.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  6. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III From Baseline to the End of the Maintenance Period

    The Unified Parkinson's Disease Rating Scale (UPDRS) Part III is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Function. It consists of 14 items with 27 questions, each ranging from 0 to 4. The sum score for the UPDRS Part III ranges from 0 to 108. A higher score indicates greater disability. A negative change score indicates improvement.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  7. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day Are Dyskinesias Present?

    Item = Duration (question #32) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - What proportion of the waking day are dyskinesias present? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  8. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Disability: How Disabling Are the Dyskinesias?

    Item = Disability (question #33) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How disabling are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  9. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Painful Dyskinesias: How Painful Are the Dyskinesias?

    Item = Painful Dyskinesia (question #34) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How painful are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  10. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Presence of Early Morning Dystonia

    Item = Presence of Early Morning Dystonia (question #35) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates early morning dystonia. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  11. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Predictable?

    Item = Are "off" periods predictable (question #36) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are predictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  12. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Unpredictable?

    Item = Are "off" periods unpredictable (question #37) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are unpredictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  13. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Do "Off" Periods Come on Suddenly?

    Item = Do "off" periods come on suddenly, within a few seconds (question #38) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods come on suddenly, within a few seconds. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  14. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day is the Subject "Off", on Average?

    Item = What proportion of the waking day is the subject "off", on average (question #39) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 - 4 points (4 = maximum). A higher score indicates the subject is "off" a larger portion of the waking day. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  15. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Anorexia, Nausea, or Vomiting?

    Item = Does the patient have anorexia, nausea, or vomiting (question #40) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has anorexia, nausea, or vomiting. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  16. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Any Sleep Disturbances Such as Insomnia or Hypersomnolence?

    Item = Does the patient have any sleep disturbances such as insomnia or hypersomnolence (question #41) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has sleep disturbances such as insomnia or hypersomnolence. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  17. The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Symptomatic Orthostasis?

    Item = Does the patient have symptomatic orthostasis (question #42) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has symptomatic orthostasis. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

  18. The Change in Number of "Off" Periods From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

    Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.

    Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].

07

Results

Posted Dec 10, 2012

Participant flow

This Phase III study started in July 2007 with subjects from the United States, Mexico, Peru, Chile, and India. The primary completion date and study completion date occurred in July 2011. The Participant Flow and Baseline Characteristics are represenative of the Safety Set (SS), which is 514 subjects.

Participant flow — Overall Study
MilestoneRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Started10110710494108
Completed7984828081
Not completed2223221427
Withdrew: Adverse event121512517
Withdrew: Lack of efficacy30227
Withdrew: Withdrawal by subject23120
Withdrew: Protocol violation11200
Withdrew: Unsatisfactory subject compliance12000
Withdrew: Lost to follow-up10422
Withdrew: Randomization error00001
Withdrew: Dispensing error10010
Withdrew: Subject moved11000
Withdrew: Sponsor request01000
Withdrew: Family problem00100
Withdrew: Site closed00010
Withdrew: Subject withdrawal00010

Outcome measures

PrimaryThe Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · Hours
The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
HoursRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary-1.948 ± 2.587-2.052 ± 3.113-2.138 ± 2.721-2.360 ± 2.608-1.499 ± 3.062
SecondaryThe Change in Relative Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · Hours
The Change in Relative Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
HoursRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
The Change in Relative Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary-12.058 ± 16.517-13.463 ± 20.099-13.410 ± 17.202-14.529 ± 16.531-9.250 ± 18.942
SecondaryThe Change in the Absolute Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · Hours
The Change in the Absolute Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
HoursRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
The Change in the Absolute Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary1.821 ± 2.6552.095 ± 3.1202.118 ± 2.8272.364 ± 2.8761.335 ± 2.975
SecondaryThe Change in the Relative Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · Hours
The Change in the Relative Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
HoursRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
The Change in the Relative Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary12.058 ± 16.51713.463 ± 20.09913.410 ± 17.20214.529 ± 16.5319.250 ± 18.942
SecondaryThe Change in the Status of the Subject After Wake-Up From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · Hours
The Change in the Status of the Subject After Wake-Up From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
HoursRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
ON Without Troublesome Dyskinesias23.688 ± 41.60724.593 ± 43.00620.935 ± 42.13221.083 ± 45.64219.712 ± 41.857
ON With Troublesome Dyskinesias-0.667 ± 18.874-0.813 ± 12.8041.626 ± 23.6591.667 ± 13.417-0.206 ± 8.934
OFF-23.021 ± 40.667-23.780 ± 43.150-22.561 ± 40.519-22.750 ± 47.193-19.506 ± 43.298
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II From Baseline to the End of the Maintenance Period

The Unified Parkinson's Disease Rating Scale (UPDRS) Part II is a scale for the assessment of function in Parkinson's disease. UPDRS Part II measures Activities of Daily Living. It consists of 13 questions, each ranging from 0 to 4. The sum score of the UPDRS Part II ranges from 0 to 52. A higher score indicates greater disability. A negative change score indicates improvement.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · units on a scale
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II From Baseline to the End of the Maintenance Period
units on a scaleRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II From Baseline to the End of the Maintenance Period-2.1 ± 4.3-2.2 ± 3.9-1.5 ± 4.7-2.1 ± 4.6-0.9 ± 3.7
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III From Baseline to the End of the Maintenance Period

The Unified Parkinson's Disease Rating Scale (UPDRS) Part III is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Function. It consists of 14 items with 27 questions, each ranging from 0 to 4. The sum score for the UPDRS Part III ranges from 0 to 108. A higher score indicates greater disability. A negative change score indicates improvement.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · units on a scale
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III From Baseline to the End of the Maintenance Period
units on a scaleRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III From Baseline to the End of the Maintenance Period-3.4 ± 7.6-4.5 ± 7.5-3.5 ± 8.9-5.9 ± 7.6-2.5 ± 8.2
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day Are Dyskinesias Present?

Item = Duration (question #32) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - What proportion of the waking day are dyskinesias present? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day Are Dyskinesias Present?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening1514131512
Equal7472756984
Improvement81510109
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Disability: How Disabling Are the Dyskinesias?

Item = Disability (question #33) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How disabling are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Disability: How Disabling Are the Dyskinesias?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening76269
Equal8089867890
Improvement10610106
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Painful Dyskinesias: How Painful Are the Dyskinesias?

Item = Painful Dyskinesia (question #34) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How painful are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Painful Dyskinesias: How Painful Are the Dyskinesias?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening23428
Equal9094868794
Improvement54853
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Presence of Early Morning Dystonia

Item = Presence of Early Morning Dystonia (question #35) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates early morning dystonia. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Presence of Early Morning Dystonia
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening597614
Equal8179787682
Improvement111313129
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Predictable?

Item = Are "off" periods predictable (question #36) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are predictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Predictable?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening6412311
Equal8082748085
Improvement111512119
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Unpredictable?

Item = Are "off" periods unpredictable (question #37) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are unpredictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Unpredictable?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening15128812
Equal7178737577
Improvement1111171116
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Do "Off" Periods Come on Suddenly?

Item = Do "off" periods come on suddenly, within a few seconds (question #38) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods come on suddenly, within a few seconds. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Do "Off" Periods Come on Suddenly?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening6711915
Equal8083756775
Improvement1111121815
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day is the Subject "Off", on Average?

Item = What proportion of the waking day is the subject "off", on average (question #39) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 - 4 points (4 = maximum). A higher score indicates the subject is "off" a larger portion of the waking day. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day is the Subject "Off", on Average?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening848711
Equal5258585561
Improvement3739323233
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Anorexia, Nausea, or Vomiting?

Item = Does the patient have anorexia, nausea, or vomiting (question #40) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has anorexia, nausea, or vomiting. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Anorexia, Nausea, or Vomiting?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening42353
Equal8896908596
Improvement53546
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Any Sleep Disturbances Such as Insomnia or Hypersomnolence?

Item = Does the patient have any sleep disturbances such as insomnia or hypersomnolence (question #41) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has sleep disturbances such as insomnia or hypersomnolence. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Any Sleep Disturbances Such as Insomnia or Hypersomnolence?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening13147412
Equal7072757778
Improvement1415161315
SecondaryThe Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Symptomatic Orthostasis?

Item = Does the patient have symptomatic orthostasis (question #42) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has symptomatic orthostasis. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Number · participants
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Symptomatic Orthostasis?
participantsRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Worsening06248
Equal9193928891
Improvement62426
SecondaryThe Change in Number of "Off" Periods From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary

Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.

Time frame:
From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Reported as:
Mean · Hours
The Change in Number of "Off" Periods From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
HoursRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
The Change in Number of "Off" Periods From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary-1.144 ± 1.687-1.294 ± 1.971-1.323 ± 1.348-1.304 ± 1.442-1.006 ± 1.474

Adverse events

Collected over Adverse Events (AEs) were collected during the course of the trial, which was approximately 33 weeks per subject.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine 2 mg/24 hr—4/101 (4%)54/101 (53.5%)
Rotigotine 4 mg/24 hr—3/107 (2.8%)54/107 (50.5%)
Rotigotine 6 mg/24 hr—2/104 (1.9%)49/104 (47.1%)
Rotigotine 8 mg/24 hr—0/94 (0%)52/94 (55.3%)
Placebo—5/108 (4.6%)54/108 (50%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
Bundle branch block leftCardiac disorders1/1010/1070/1040/940/108
Gastrointestinal haemorrhageGastrointestinal disorders1/1010/1070/1040/940/108
OrchitisInfections and infestations1/1010/1070/1040/940/108
Mental status changesPsychiatric disorders1/1010/1070/1040/940/108
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/1010/1070/1040/940/108
Acetabulum fractureInjury, poisoning and procedural complications1/1010/1070/1040/940/108
Pubic rami fractureInjury, poisoning and procedural complications1/1010/1070/1040/940/108
FallInjury, poisoning and procedural complications0/1011/1071/1040/940/108
Brain herniationInjury, poisoning and procedural complications0/1010/1071/1040/940/108
Head injuryInjury, poisoning and procedural complications0/1010/1071/1040/940/108
Most frequent other events
Showing 10 of 19
Most frequent other events
EventRotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlacebo
DyskinesiaNervous system disorders5/1014/10711/10414/943/108
NauseaGastrointestinal disorders13/10111/10715/10411/948/108
HeadacheNervous system disorders10/1018/1076/1048/9412/108
DizzinessNervous system disorders8/10111/1077/1046/949/108
SomnolenceNervous system disorders7/1016/1078/1044/949/108
ConstipationGastrointestinal disorders1/1014/1078/1044/948/108
Application site pruritusGeneral disorders4/1016/1078/1047/942/108
InsomniaPsychiatric disorders6/1018/1076/1046/947/108
FatigueGeneral disorders7/1015/1072/1044/946/108
Urinary tract infectionInfections and infestations7/1012/1072/1041/944/108

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlaceboTotal
<=18 years000000
Between 18 and 65 years4654474948244
>=65 years5553574560270
Age, Continuous
Age, Continuous(years)Rotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlaceboTotal
Mean65.4 ± 10.564.6 ± 9.064.6 ± 10.463.2 ± 11.664.8 ± 10.264.5 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlaceboTotal
Female2428313834155
Male7779735674359
Region of Enrollment
Region of Enrollment(participants)Rotigotine 2 mg/24 hrRotigotine 4 mg/24 hrRotigotine 6 mg/24 hrRotigotine 8 mg/24 hrPlaceboTotal
United States6672685969334
Mexico112015
Peru4324316
Chile221229
India2829312933150
08

Study locations

77 sites
  • Birmingham, Alabama, United States
  • Tuscaloosa, Alabama, United States
  • Gilbert, Arizona, United States
  • Peoria, Arizona, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Little Rock, Arkansas, United States
  • Fountain Valley, California, United States
  • Fresno, California, United States
  • Irvine, California, United States
  • La Jolla, California, United States
  • Loma Linda, California, United States
  • Oxnard, California, United States
  • Aurora, Colorado, United States
  • New Haven, Connecticut, United States
  • Boca Raton, Florida, United States
  • Bradenton, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Naples, Florida, United States
  • Ocala, Florida, United States
  • Ormond Beach, Florida, United States
  • Pompano Beach, Florida, United States
  • St. Petersburg, Florida, United States
  • Sunrise, Florida, United States
  • Atlanta, Georgia, United States
  • Decatur, Georgia, United States
  • Macon, Georgia, United States
  • Suwanee, Georgia, United States
  • Chicago, Illinois, United States
  • Anderson, Indiana, United States
  • Des Moines, Iowa, United States
  • Kansas City, Kansas, United States
  • Louisville, Kentucky, United States
  • Southfield, Michigan, United States
  • Golden Valley, Minnesota, United States
  • St Louis, Missouri, United States
  • Missoula, Montana, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Commack, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Raleigh, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Columbus, Ohio, United States
  • Toledo, Ohio, United States
  • Greensburg, Pennsylvania, United States
  • Souderton, Pennsylvania, United States
  • Upland, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Lubbock, Texas, United States
  • San Antonio, Texas, United States
  • Midvale, Utah, United States
  • South Ogden, Utah, United States
  • Alexandria, Virginia, United States
  • Richmond, Virginia, United States
  • Roanoke, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Kirkland, Washington, United States
  • Spokane, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Santiago de Chile, Chile
  • Hyderbad, Andhra Pradesh, India
  • Bangalore, Kamataka, India
  • Mangalore, Kamataka, India
  • Mysore, Karnataka, India
  • Calicut, Kerala, India
  • Thiruvananthapuram, Kerala, India
  • Indore, Madhya Pradesh, India
  • Mumbai, Maharashtra, India
  • Pune, Maharashtra, India
  • Chennai, Tamil Nadu, India
  • Monterrey, Nuevo Leon, Mexico
  • Aguascalientes, Mexico
  • San Isidro, Lima, Peru
  • Santiago de Surco, Lima, Peru
09

References and documents

Publications

  • LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133. PubMed 26882318 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2007
First posted
Aug 29, 2007
Start
Jul 2007
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Dec 10, 2012
Last update
Oct 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00522379
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Aug 29, 2007
Start date
Jul 2007
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Dec 10, 2012
Last update
Oct 27, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion